Selecta Biosciences - Stock Price History | SELB

Historical daily share price chart and data for Selecta Biosciences since 2021 adjusted for splits. The latest closing stock price for Selecta Biosciences as of September 27, 2021 is 4.44.
  • The all-time high Selecta Biosciences stock closing price was 26.33 on November 25, 2016.
  • The Selecta Biosciences 52-week high stock price is 5.70, which is 28.4% above the current share price.
  • The Selecta Biosciences 52-week low stock price is 1.47, which is 66.9% below the current share price.
  • The average Selecta Biosciences stock price for the last 52 weeks is 3.74.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Selecta Biosciences Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2020 2.9182 2.3000 4.5200 1.5000 3.0300 27.31%
2019 1.9374 2.9000 3.0600 1.3200 2.3800 -10.53%
2018 10.5935 10.2400 16.0000 2.6600 2.6600 -72.88%
2017 15.2652 17.2800 23.3800 8.9700 9.8100 -42.80%
2016 16.1111 14.0000 26.3300 10.6500 17.1500 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.511B $0.017B
Selecta Biosciences, Inc. is a biopharmaceutical company which develops targeted immunotherapies and vaccines. Its product pipelineincludes gene therapy, food allergy, malaria; SEL-212, which is a therapeutic enzyme indicated for refractory gout; SEL-070, which is indicated for smoking cessation and relapse prevention; SEL-701, which is indicated for the treatment of human papillomavirus associated cancer and SEL-212 consists of SVP-Rapamycin co-administered with pegsiticase, its pegylated uricase. Selecta Biosciences, Inc. is based in Watertown, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $132.971B 8.85
Bio-Rad Laboratories (BIO.B) United States $22.624B 48.22
QIAGEN (QGEN) Netherlands $12.001B 20.32
Biohaven Pharmaceutical Holding (BHVN) United States $8.691B 0.00
Emergent Biosolutions (EBS) United States $2.870B 6.92
Arcus Biosciences (RCUS) United States $2.690B 0.00
Myovant Sciences (MYOV) United Kingdom $2.182B 0.00
ADC Therapeutics SA (ADCT) Switzerland $2.045B 0.00
Zymeworks (ZYME) Canada $1.373B 0.00
Ambrx Biopharma (AMAM) United States $0.501B 0.00
SQZ Biotechnologies (SQZ) United States $0.442B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29